1. Revolution Medicines, Inc. (NASDAQ:RVMD)
Upside Potential: 81.09%
Stock Price as of January 16: $40.55
Number of Hedge Fund Investors: 32
Revolution Medicines, Inc. (NASDAQ:RVMD) is a clinical-stage oncology company developing precision medicines targeting RAS-driven cancers. The company pipeline focuses on therapies that inhibit specific oncogenic proteins associated with difficult-to-treat cancers. Revolution Medicines, Inc.’s (NASDAQ:RVMD) proprietary RAS(ON) platform is designed to selectively target the oncogenic RAS protein state, a key driver in numerous cancers, including pancreatic ductal adenocarcinoma (PDAC) and non-small cell lung cancer (NSCLC).
Revolution Medicines, Inc. (NASDAQ:RVMD) is actively working on the advancement of RMC-6236, a first-in-class RAS(ON) multi-selective inhibitor. The company has made significant strides in demonstrating the efficacy and safety of RMC-6236, particularly in the treatment of metastatic PDAC, a deadly cancer that spreads from the pancreas. Recent data from the Phase 1/2 study showed impressive progression-free survival (PFS) and overall survival (OS) rates, with a median PFS of 8.5 months and a median OS of 14.5 months in patients who had received one prior chemotherapy regimen.
These results have led to the initiation of a global, randomized Phase 3 study, RASolute 302, which is actively recruiting patients. The success of this study could potentially establish RMC-6236 as a new standard of care for second-line treatment in metastatic PDAC, significantly expanding the company’s market reach and therapeutic impact.
Revolution Medicines, Inc. (NASDAQ:RVMD) is also making significant progress in the development of RAS(ON) inhibitors for non-small cell lung cancer (NSCLC). The company is advancing RMC-6236 and RMC-6291, a RAS(ON) G12C selective inhibitor, through various monotherapy and combination studies. The upcoming data disclosures, including updated RMC-6236 monotherapy activity data and initial data from exploratory combination studies, are expected to provide valuable insights into the potential of these therapies. The company aims to initiate a Phase 3 registrational study evaluating RMC-6236 as a monotherapy in previously treated advanced RAS mutant NSCLC in the first quarter of 2025.
While we acknowledge the potential of Revolution Medicines, Inc. (NASDAQ:RVMD) to grow, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns and doing so within a shorter timeframe. If you are looking for an AI stock that is more promising than RVMD but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock.
READ NEXT: 20 Best AI Stocks To Buy Now and Complete List of 59 AI Companies Under $2 Billion in Market Cap.
Disclosure. None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and investors. Please subscribe to our daily free newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email address below.
